uniQure to Participate in Multiple Upcoming Industry Conferences in February
February 01 2021 - 7:05AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced its participation in the following upcoming
virtual investor and scientific conferences:
-
14th Annual Congress of
the European Association of Hemophilia and Allied Disorders
(EAHAD), February 3 – 5, 2021
• uniQure will
deliver multiple presentations on the company’s gene therapy
candidate etranacogene dezaparvovec in patients with hemophilia B.
These presentations will include encore clinical data first
presented at medical conferences late last year, as well as health
economic data.
• Further details on
the company’s presentations will follow closer to the conference
dates.
- Gene Therapy Medical
Affairs, February 9 -11, 2021
• Eileen Sawyer,
Ph.D., vice president, global medical affairs of uniQure, will
present “Medical Affairs as Partner to Empower Patients Throughout
the Drug Development Process” on Wednesday, February 10 at 12:20
p.m. ET.
• Nick Li.,
Ph.D., senior director, healthcare economics and outcomes research
(HEOR) of uniQure, will present “Explore Delivering Therapy Gene
Therapy to Patients” on Thursday, February 11 at 11:50 a.m. ET.
-
10th Annual SVB Leerink
Global Healthcare Conference, February 22 – 26, 2021
• A fireside
chat with Matt Kapusta, chief executive officer, will take place on
February 26, 2021 from 3:00 to 3:30 p.m. ET. The live webcast of
the fireside chat can be accessed through the link displayed in the
Investor section of the uniQure website. The webcast replay will be
available for at least 72 hours following the live event.
• Members of
uniQure’s management team including Matt Kapusta, Ricardo
Dolmetsch, Ph.D., president of research & development, and
Maria Cantor, chief communications officer, with Chiara Russo,
associate director of investor relations and communications, will
participate in virtual one-on-one investor meetings throughout the
day.
-
65th Annual Meeting of
the Society of Thrombosis and Haemostasis Research (GTH), February
22 – 26, 2021
• Professor
Wolfgang Miesbach, M.D., Ph.D., of the University Hospital
Frankfurt in Germany, will present two-year follow-up data on
etranacogene dezaparvovec in hemophilia B, as well as five-year
follow-up data on AMT-060, also in patients with hemophilia B.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3
and other diseases. www.uniQure.com
|
|
|
uniQure
Contacts: |
|
|
|
|
|
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E.
Cantor |
Chiara
Russo |
Tom
Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
|
|
|
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024